ScaleReady Announces Award of a G-Rex庐 Grant to the Gates Institute's Translational Sciences Laboratory
ScaleReady (NYSE:TECH) has awarded a $300,000 G-Rex庐 Grant to the Gates Institute's Translational Sciences Laboratory to develop a modular CAR T-cell manufacturing platform. The grant will support optimization of key CAR-T cell manufacturing steps through Design of Experiments (DoE) evaluation.
The Gates Institute will receive early access to CellReady's 骋-颁础搁-罢鈩�, a standardized CAR-T drug product manufacturing operation. ScaleReady's G-Rex Grant Program has authorized over $40M of products to grant recipients to advance cell and gene therapy development and manufacturing.
Additionally, ScaleReady announced a new free program called LEAN Cell & Gene鈩�, launched in partnership with Hanson Wade, aimed at improving efficiency in CGT manufacturing.
ScaleReady (NYSE:TECH) ha assegnato al Translational Sciences Laboratory del Gates Institute una borsa G-Rex庐 da 300.000 $ per sviluppare una piattaforma modulare per la produzione delle cellule CAR-T. La borsa sosterr脿 l'ottimizzazione delle fasi chiave della produzione CAR-T mediante valutazioni basate sul Design of Experiments (DoE).
Il Gates Institute avr脿 accesso anticipato al 骋-颁础搁-罢鈩� di CellReady, un processo standardizzato per la produzione del prodotto farmaceutico CAR-T. Il programma G-Rex Grant di ScaleReady ha autorizzato oltre 40 milioni di dollari in prodotti ai beneficiari per promuovere lo sviluppo e la produzione di terapie cellulari e geniche.
Inoltre, ScaleReady ha annunciato un nuovo programma gratuito chiamato LEAN Cell & Gene鈩�, lanciato in collaborazione con Hanson Wade, volto a migliorare l'efficienza nella produzione di terapie cellulari e geniche (CGT).
ScaleReady (NYSE:TECH) ha otorgado al Translational Sciences Laboratory del Gates Institute una Subvenci贸n G-Rex庐 de $300,000 para desarrollar una plataforma modular de fabricaci贸n de c茅lulas CAR-T. La subvenci贸n apoyar谩 la optimizaci贸n de pasos clave en la fabricaci贸n de CAR-T mediante evaluaciones de Design of Experiments (DoE).
El Gates Institute tendr谩 acceso temprano al 骋-颁础搁-罢鈩� de CellReady, una operaci贸n estandarizada para la fabricaci贸n de productos farmac茅uticos CAR-T. El programa G-Rex Grant de ScaleReady ha autorizado m谩s de 40 millones de d贸lares en productos a los beneficiarios para impulsar el desarrollo y la producci贸n de terapias celulares y g茅nicas.
Adem谩s, ScaleReady anunci贸 un nuevo programa gratuito llamado LEAN Cell & Gene鈩�, lanzado en asociaci贸n con Hanson Wade, que busca mejorar la eficiencia en la fabricaci贸n de CGT (terapias celulares y g茅nicas).
ScaleReady (NYSE:TECH)臧� 瓴岇澊旄� 鞐瓣惮靻岇潣 Translational Sciences Laboratory鞐� 氇搱順� CAR-T 靹疙彫 鞝滌“ 頂岆灚韽� 臧滊皽鞚� 鞙勴暣 $300,000 G-Rex庐 氤挫“旮�鞚� 靾橃棳頄堨姷雼堧嫟. 鞚� 氤挫“旮堨潃 鞁ろ棙瓿勴殟氩�(Design of Experiments, DoE)鞚� 韱淀暅 頃奠嫭 CAR-T 鞝滌“ 雼硠鞚� 斓滌爜頇旊ゼ 歆�鞗愴暕雼堧嫟.
瓴岇澊旄� 鞐瓣惮靻岆姅 CellReady鞚� 骋-颁础搁-罢鈩�鞐� 雽�頃� 臁瓣赴 鞝戧芳 甓岉暅鞚� 氚涥矊 霅橂┌, 鞚措姅 響滌頇旊悳 CAR-T 鞚橃暯頀� 鞝滌“ 鞖挫榿鞛呺媹雼�. ScaleReady鞚� G-Rex Grant 頂勲攴鸽灗鞚� 靹疙彫 氚� 鞙犾爠鞛� 旃橂 臧滊皽瓿� 鞝滌“毳� 齑夓頃橁赴 鞙勴暣 靾橅槣鞛愳棎瓴� 齑� 4觳滊 雼煬 鞚挫儊 靸侂嫻鞚� 鞝滍拡鞚� 鞀轨澑頄堨姷雼堧嫟.
霕愴暅 ScaleReady電� Hanson Wade鞕� 順戨牓頃橃棳 CGT(靹疙彫 氚� 鞙犾爠鞛� 旃橂) 鞝滌“ 須湪靹膘潉 臧滌劆頃橁赴 鞙勴暅 氍措 頂勲攴鸽灗鞚� LEAN Cell & Gene鈩�鞚� 靸堧 於滌嫓頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟.
ScaleReady (NYSE:TECH) a octroy茅 au Translational Sciences Laboratory du Gates Institute une subvention G-Rex庐 de 300 000 $ pour d茅velopper une plateforme modulaire de fabrication de cellules CAR-T. La subvention soutiendra l'optimisation des 茅tapes cl茅s de fabrication des CAR-T via des 茅valuations par Design of Experiments (DoE).
Le Gates Institute b茅n茅ficiera d'un acc猫s anticip茅 au 骋-颁础搁-罢鈩� de CellReady, une op茅ration standardis茅e de production de m茅dicament CAR-T. Le programme G-Rex Grant de ScaleReady a autoris茅 plus de 40 millions de dollars de produits aux b茅n茅ficiaires pour faire progresser le d茅veloppement et la fabrication de th茅rapies cellulaires et g茅niques.
De plus, ScaleReady a annonc茅 un nouveau programme gratuit nomm茅 LEAN Cell & Gene鈩�, lanc茅 en partenariat avec Hanson Wade, visant 脿 am茅liorer l'efficacit茅 dans la fabrication des CGT (th茅rapies cellulaires et g茅niques).
ScaleReady (NYSE:TECH) hat dem Translational Sciences Laboratory des Gates Institute einen $300.000 G-Rex庐-Zuschuss zur Entwicklung einer modularen CAR-T-Zellproduktionsplattform bewilligt. Der Zuschuss unterst眉tzt die Optimierung zentraler Herstellungsstufen f眉r CAR-T-Zellen durch Evaluierungen mittels Design of Experiments (DoE).
Das Gates Institute erh盲lt Fr眉hzugang zu CellReady's 骋-颁础搁-罢鈩�, einem standardisierten Herstellungsprozess f眉r CAR-T-Arzneimittel. Das G-Rex Grant-Programm von ScaleReady hat Empf盲ngern Produkte im Wert von insgesamt 眉ber 40 Millionen US-Dollar zur F枚rderung der Entwicklung und Produktion von Zell- und Gentherapien bewilligt.
Au脽erdem k眉ndigte ScaleReady ein neues, kostenloses Programm namens LEAN Cell & Gene鈩� an, das in Partnerschaft mit Hanson Wade gestartet wurde und die Effizienz in der CGT-Produktion verbessern soll.
- Grant program has authorized over $40M in products to advance cell and gene therapy development
- Launch of new free LEAN Cell & Gene鈩� program to improve manufacturing efficiency
- Early access provided to 骋-颁础搁-罢鈩� standardized manufacturing operation
- None.
Insights
ScaleReady's $300,000 G-Rex Grant to Gates Institute advances CAR-T manufacturing platforms, positioning Bio-Techne for growth in the cell therapy space.
The $300,000 G-Rex Grant awarded to Gates Institute represents a strategic investment in optimizing CAR-T cell manufacturing processes. This collaboration between ScaleReady (a partnership including Bio-Techne and Wilson Wolf) and the respected CDMO at University of Colorado Anschutz Medical Campus targets a critical bottleneck in cell therapy development.
The grant focuses on developing a modular G-Rex centric CAR-T manufacturing platform through structured Design of Experiments (DoE) methodology鈥攁 sophisticated approach that systematically evaluates critical variables to optimize manufacturing steps. This scientific rigor will generate valuable intellectual property and process knowledge that could significantly enhance Bio-Techne's competitive positioning in the cell therapy tools market.
What makes this particularly noteworthy is the access to CellReady's 骋-颁础搁-罢鈩� standardized manufacturing operation, which emphasizes high-throughput, low-cost manufacturing鈥攁ddressing the fundamental cost challenges that have limited broader adoption of cell therapies. The initiative aligns with industry-wide efforts to reduce manufacturing complexity, improve scalability, and lower production costs for advanced therapies.
The broader context of ScaleReady's $40M authorized product grants and the launch of their LEAN Cell & Gene鈩� program indicates a coordinated strategy to establish their G-Rex platform as an industry standard in cell therapy manufacturing. For Bio-Techne, this represents potential for expanded market share in the rapidly growing cell and gene therapy tools sector, particularly in simplified, scalable manufacturing solutions that address current industry pain points.
"We are grateful for the generous G-Rex Grant funding, which will support the development of efficient and adaptable manufacturing approaches for our cell and gene therapy (CGT) programs," said Dr. Veena Krishnamoorthy, Director of Translational Sciences at the Gates Institute. "The scalable and modular nature of the G-Rex platform aligns with our goals to optimize use of space, capital, and personnel while maintaining cell health and quality. We appreciate the support from Wilson Wolf and Bio-Techne in advancing our work and the broader CGT field."
"We are pleased to award G-Rex Grant funding to the Gates Institute, a leader in bridging the academic world of discovery with clinical application to advance a diverse portfolio of innovative cell therapies for devastating cancers and rare diseases. It's an honor to support the Gates Institute's important contributions to the field of cell and gene therapy." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
The G-Rex Grant will support a structured Design of Experiments (DoE) to optimize key CAR-T cell manufacturing steps by systematically evaluating critical variables. The resulting data will continue to define and optimize how process conditions impact product attributes, enabling the Gates Institute to offer a broad range of manufacturing options within standardized, well-characterized design spaces for novel cell and gene therapies.
As part of the G-Rex Grant, the Gates Institute will also receive early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation conceived of by CellReady, the world's first and only G-Rex CDMO.聽 G-CAR-TTM is ideal for high-throughput, low-cost manufacturing.
ScaleReady's G-Rex Grant Program has authorized over
Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program, ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & GeneTM.聽 All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing.
For more information about LEAN Cell & GeneTM, please use this link to register聽for the free event series.
About Gates Institute
Gates Institute is a world-class translational research institute with biomanufacturing capabilities. Based at the University of Colorado Anschutz Medical Campus, the institute is part of a rich biomedical ecosystem, enabling the development of life-saving treatments for a host of diseases at unmatched speed and scope. Gates Institute brings together and supports researchers and clinicians who specialize in regenerative, cell and gene therapies, accelerating their discoveries from concepts to cures.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex庐 Grant Program, please contact [email protected].
About Wilson Wolf Manufacturing
Wilson Wolf () is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing.聽 This is being accomplished through its fully scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex庐 device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex庐 Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit 聽or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
[email protected]
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex庐 process at a time.
View original content to download multimedia:
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to Gates Institute by ScaleReady (NYSE:TECH)?
How much has ScaleReady's G-Rex Grant Program authorized in total product value?
What is the purpose of ScaleReady's G-Rex Grant to Gates Institute?
What is the new program launched by ScaleReady in 2025?
What additional benefit does Gates Institute receive with the G-Rex Grant?
